Merck Sharp + Dohme Corp.

Schering Corporation

University of Pittsburgh

Other

Merck Canada Inc.

Pharacopeia Drug Discovery, Inc.

Hubert B Josien

John W Clader

Anandan Palani

Dmitri A Pissarnitski

Dennis Patrick Curran

Theodros Asberom

Thomas A Bara

Duane A Burnett

Hongmei Li

Ruo Xu

Michael W Miller

Zhiqiang Zhao

Bernard R Neustadt

Brian Alexander McKittrick

Stuart W McCombie

Elizabeth M Smith

Jayaram R Tagat

Susan F Vice

William J Greenlee

Zhaoning Zhu

Xianhai Huang

Wen-Lian Wu

Thomas Joseph Tucker

Fa-Xiang Ding

Eric J Gilbert

Purakkattle J Biju

Anilkumar G Nair

Abbas M Walji

William K Hagmann

Ravi P Nargund

Bin Hu

Jian Liu

Harold B Wood

Christopher W Plummer

Marc A Labroli

Thavalakulamgara K Sasikumar

Chad E Bennett

Tesfaye Biftu

Qun Dang

Elisabetta Bianchi

Yusheng Xiong

Cheng Zhu

Zhengxia Chen

Angela Dawn Kerekes

Timothy Allen Blizzard

Jun Qin

Barbara A Pio

Tao Guo

Srikanth Venkatraman

Steven L Colletti

Ling Tong

Michael Man-Chu Lo

Liangqin Guo

Douglas Walsh Hobbs

Jing Su

Bing Li

Linus S Lin

Harry R Chobanian

Yan Guo

Zhong-Yue Sun

Shouwu Miao

Francisco Velazquez

Unmesh G Shah

Haiqun Tang

Sookhee Nicole Ha

Samuel Chackalamannil

Yongxin Han

Robert G Aslanian

Scott D Edmondson

Dong Xiao

Feroze Ujjainwalla

Yan Xia

Malcolm Maccoss

Jason M Cox

John S Debenham

Robert D Mazzola, Jr

Bowei Wang

Patrick A Pinto

Zhuyan Guo

Derun Li

Jesse K Wong

Santhosh Francis Neelamkavil

Johannes H Voigt

Yu Jiang

De-Yi Yang

Mariappan Chelliah

Robert Jason Herr

Timothy A Blizzard

Thomas G Burke

Xiaohong Zhu

Takao Suzuki

Linda Brockunier

Wei Zhou

Quang T Truong

Jessica Frie

Martin C Clasby

Raffaele Ingenito

Sobhana Babu Boga

Xiaoxiang Liu

Ping Lan

Disclosed are compounds of Formula I, or a salt thereof:

PCSK9 antagonist compounds

Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof: where A, X, R, and Rare as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

Disclosed are compounds of Formula I, or a salt thereof: where A, B, D, X, R, Rand Rare as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

Disclosed are compounds of Formula I, or a salt thereof cyclic polypeptide of Formula I: Formula I where A, B, E, R, and Rare as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions 

PCSK9 antagonists bicyclo-compounds

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic tricyclic compounds

Antidiabetic bicyclic compounds

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic substituted heteroaryl compounds

This invention provides for certain bridged and fused compounds of the formulaG-L-A&#x2003;&#x2003;Ior a pharmaceutically acceptable salt, ester of solvate thereofwherein: and the other variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates to pharmaceutical compositions containing these compounds, and the use of these compounds to regulate insulin levels in a mammal. The compounds may be used, for example in the prevention and treatment of Type 2 diabetes mellitus and in the prevention and treatment of conditions related to Type 2 diabetes mellitus, such as insulin resistance, obesity and lipid disorders.

Bridged and fused antidiabetic compounds

The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.

HCV NS3 protease inhibitors

In its many embodiments, the present invention provides a novel class of heterocyclic compounds of the formula: as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more disease associated with the central nervous system using such compounds or pharmaceutical compostions. 

Gamma secretase modulators

Growing community of inventors

Jersey City, NJ, United States of America

Hubert B Josien